Table 3

Comparative risks of TB occurrence between JAK inhibitors and bDMARD using patients with RA in the propensity score-matched cohort

Exposure varianceStudy groupTB cases, n (%)Time to onset, median (range), weeksPYIR per 100 PY (95% CI)HR (95% CI)
UnadjustedAdjusted
Window period of 6 months and follow-up for 5 yearsbDMARD186 (1.4)43.3 (0.1–254.9)40 6130.46 (0.39 to 0.52)Reference
JAK inhibitor15 (0.4)51.1 (0.1–169.4)78830.19 (0.09 to 0.29)0.37 (0.22 to 0.62)0.37 (0.22 to 0.62)
Window period of 12 months and follow-up for 5 yearsbDMARD192 (1.4)45.5 (0.1–254.9)43 7220.44 (0.38 to 0.5)Reference
JAK inhibitor15 (0.4)51.1 (0.1–169.4)81260.18 (0.09 to 0.28)0.37 (0.22 to 0.62)0.37 (0.22 to 0.62)
Window period of 12 months and follow-up until the end of the studybDMARD199 (1.5)50.4 (0.1–483.0)50 8360.39 (0.34 to 0.45)Reference
JAK inhibitor15 (0.4)51.1 (0.1–169.4)79150.19 (0.09 to 0.29)0.37 (0.22 to 0.62)0.37 (0.22 to 0.63)
Window period of 12 months and follow-up until the end of the studybDMARD207 (1.5)52.9 (0.1–483.0)55 0890.38 (0.32 to 0.43)Reference
JAK inhibitor15 (0.4)51.1 (0.1–169.4)81600.18 (0.09 to 0.28)0.37 (0.22 to 0.62)0.37 (0.22 to 0.63)
  • bDMARD, biological disease-modifying antirheumatic drug; IR, incidence rate; JAK, Janus kinase; PY, person-year; RA, rheumatoid arthritis; TB, tuberculosis.